Get the Stockscreener App
0.5673
4.97%
-0.0297
Windtree Therapeutics Inc stock is traded at $0.5673, with a volume of 348.08K.
It is down -4.97% in the last 24 hours and down -31.49% over the past month.
Windtree Therapeutics Inc is a biotechnology company focused on advancing early and late-stage therapies for critical conditions and diseases. Its portfolio of product candidates includes istaroxime, a Phase 2 candidate with sarco endoplasmic reticulum Ca2+ -ATPase 2a, or SERCA2a, activating properties for acute heart failure and associated cardiogenic shock, preclinical SERCA2a activators for heart failure, rostafuroxin for the treatment of hypertension in patients with a specific genetic profile, and a preclinical atypical protein kinase C iota, or aPKCi, inhibitor, being developed for potential application in rare and broad oncology indications. It operates in one operating segment, which is the research and development of products focused on cardiovascular disease.
See More
Previous Close:
$0.597
Open:
$0.5957
24h Volume:
348.08K
Relative Volume:
0.08
Market Cap:
$2.93M
Revenue:
-
Net Income/Loss:
$-11.38M
P/E Ratio:
-0.0205
EPS:
-27.73
Net Cash Flow:
$-12.72M
1W Performance:
-18.93%
1M Performance:
-31.49%
6M Performance:
+57.58%
1Y Performance:
-82.85%
1-Day Range:
$0.545
$0.597
1-Week Range:
$0.5377
$0.6498
52-Week Range:
$0.0915
$14.75
Windtree Therapeutics Inc Stock (WINT) Company Profile
Name
Windtree Therapeutics Inc
Sector
Industry
Phone
(215) 488-9300
Address
2600 KELLY ROAD, WARRINGTON, PA
Compare WINT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
WINT
Windtree Therapeutics Inc
|
0.5673 | 2.93M | 0 | -11.38M | -12.72M | -27.73 |
|
VRTX
Vertex Pharmaceuticals Inc
|
447.81 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
516.48 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
316.91 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
544.77 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
256.24 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Windtree Therapeutics Inc Stock (WINT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-26-20 | Initiated | Ladenburg Thalmann | Buy |
Windtree Therapeutics Inc Stock (WINT) Latest News
Warrington’s Windtree Therapeutics Acquires Waste Management Company - MSN
Windtree Therapeutics Announces Promising Phase 2 Study Results for Istaroxime - MyChesCo
Windtree Therapeutics (WINT) Publishes Promising Phase 2 Study R - GuruFocus
Ratios Revealed: Decoding Windtree Therapeutics Inc (WINT)’s Financial Health - DWinneX
Windtree Announces Publication of Istaroxime Positive Phase 2 SEISMiC B Study | WINT Stock News - GuruFocus
Windtree Announces Publication of Istaroxime Positive Phase 2 SEISMiC B Study - Yahoo Finance
Windtree Therapeutics, Inc. (NASDAQ:WINT) Short Interest Up 70.4% in May - Defense World
Windtree Therapeutics Acquires Titan Environmental Services to Drive Profitability - MSN
Windtree Therapeutics Receives $7 Million Offer for Preclinical Oncology Platform - MSN
Titan Environmental to be acquired by Windtree Therapeutics - Investing.com Nigeria
Titan Environmental to be acquired by Windtree Therapeutics By Investing.com - Investing.com South Africa
Windtree Therapeutics Stock Is Volatile This Week: What's Going On? - Benzinga
Windtree Therapeutics to acquire Titan Environmental Services - MSN
Windtree Therapeutics receives $7M offer for oncology platform By Investing.com - Investing.com South Africa
Warrington’s Windtree Therapeutics Acquires A Waste Management Company - BUCKSCO.Today
Windtree Therapeutics Raises $3.9M Through Note Agreements - TipRanks
Windtree Therapeutics (WINT) Receives Offer for Oncology Platfor - GuruFocus
Windtree Receives Offer for Its Preclinical Oncology Drug Candidate - The Manila Times
Windtree Therapeutics (WINT) Receives Offer for Oncology Platform | WINT Stock News - GuruFocus
Windtree Therapeutics receives offer for preclinical oncology drug candidate - TipRanks
Windtree Therapeutics receives $7M offer for oncology platform - Investing.com Australia
Windtree Therapeutics, Inc. Secures $7 Million Up Front for Preclinical Oncology Drug Candidate, Potentially Worth $130 Million in Milestones and $1.5 Billion in Royalties - Nasdaq
Windtree's $1.5 Billion Oncology Drug Deal Signals Major Strategic ShiftSee Full Terms - Stock Titan
Working to clean up its finances, Windtree Therapeutics gets into the garbage business - The Business Journals
Windtree to Acquire Titan Environmental Services; Shares Surge - marketscreener.com
Windtree Stock Is Rising Tuesday: What's Going On? - Benzinga
Windtree Therapeutics (WINT) to Acquire Titan Environmental Serv - GuruFocus
Windtree Announces Transformational Agreement To Acquire Revenue Generating Environmental Services Business - marketscreener.com
Windtree Therapeutics announces agreement to acquire Titan Environmental - TipRanks
Windtree Therapeutics (WINT) Acquires Titan Environmental Services to Enhance Profitability | WINT Stock News - GuruFocus
Windtree Announces Transformational Agreement to Acquire Revenue Generating Environmental Services Business - Yahoo Finance
Windtree Therapeutics Announces Move into Cryptocurrency Payments and Holdings - MSN
Windtree Announces Plan for Cryptocurrency Treasury Policy | WIN - GuruFocus
Windtree Therapeutics to accept cryptocurrency payments - Investing.com Australia
Windtree Therapeutics to accept cryptocurrency payments By Investing.com - Investing.com South Africa
Windtree Therapeutics announces plan for cryptocurrency treasury policy - TipRanks
Windtree Therapeutics (WINT) Embraces Cryptocurrency as Payment Option | WINT Stock News - GuruFocus
Windtree Therapeutics (WINT) to Accept Cryptocurrency Payments: A Strategic Shift Amid Financial Challenges - Coinfomania
Windtree Therapeutics Creates Cryptocurrency Treasury Plan - marketscreener.com
Windtree Therapeutics IncTo Create Cryptocurrency Policy For Payments And Assets - marketscreener.com
Major Biotech Company Windtree Embraces Crypto: Plans Bitcoin Payments and Digital Asset Treasury Strategy - Stock Titan
Short Interest in Windtree Therapeutics, Inc. (NASDAQ:WINT) Increases By 110.2% - Defense World
Windtree Therapeutics Targets July for Interim Data from Key Cardiogenic Shock Study - MSN
Windtree Showcases Promising Istaroxime Data for Cardiogenic Shock at Major Conference - MSN
Windtree Therapeutics (WINT) Targets Key Study Analysis for July 2025 | WINT Stock News - GuruFocus
Windtree says interim results for SEISMiC SCAI Stage C study set for July 2025 - TipRanks
Windtree Therapeutics Announces Istaroxime Cardiogenic Shock SCAI Stage C Phase 2 Study Planned Interim Analysis Results Targeted for July 2025 - marketscreener.com
Windtree Therapeutics Announces Istaroxime Cardiogenic Shock SCAI Stage C Phase 2 Study Planned Interim Analysis Results Targeted for July 2025 | WINT Stock News - GuruFocus
Windtree Therapeutics Advances Istaroxime Cardiogenic Shock Program with SEISMiC C Study Interim Analysis Planned for July 2025 - Nasdaq
Critical Phase 2 Data Coming for Istaroxime in Severe Cardiogenic Shock Treatment - Stock Titan
Windtree Therapeutics Inc Stock (WINT) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.59%
0.56%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):